Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Pembrolizumab (Keytruda)
Treatment for Bladder cancer
Typical Dosage: 200 mg IV every 3 weeks or 400 mg IV every 6 weeks
Effectiveness
65%
Safety Score
50%
Clinical Trials
117
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe
Treatment Details
Dosage Range
200 mg IV every 3 weeks or 400 mg IV every 6 weeks
Time to Effect
3-6 months
Treatment Duration
Up to 2 years or until progression
Evidence Quality
HIGHNumber Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
8(Treat 8 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$130,000
Monitoring:$7,500
Side Effect Mgmt:$10,000
Total Annual:$147,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$130,000/QALY
QALYs Gained
1.5
Outcome-Based Costs
Cost per Responder
$590,000
Cost per Remission
$2,107,142.86
Comparison vs Taxane chemotherapy (e.g., Paclitaxel)
Cost Difference
+$100,000/year
More expensive
QALY Difference
+0.70 QALYs
Better outcomes
Dominance
No dominance
Pembrolizumab (Keytruda) Outcomes
for Bladder cancer
Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+25%
Remission Rate
+7%
Common Side Effects
Fatigue
+25%
Pruritus (itching), rash
+20%
Diarrhea/Colitis
+12%
Hypothyroidism
+7%
Pneumonitis, hepatitis, nephritis (severe irAEs)
+3%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
8 active trials recruiting for Pembrolizumab (Keytruda) in Bladder cancer
Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]
NCT03504163ACTIVE NOT RECRUITINGPHASE2
45 participants
INTERVENTIONAL
Basking Ridge, United States +6 more
Started: Jun 27, 2018
Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer
NCT05072600RECRUITINGPHASE2
54 participants
INTERVENTIONAL
Beijing, China
Started: Dec 7, 2021
Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)
NCT05879653RECRUITINGPHASE2
30 participants
INTERVENTIONAL
Kobe, Japan +3 more
Started: Oct 1, 2023
Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder
NCT02621151ACTIVE NOT RECRUITINGPHASE2
60 participants
INTERVENTIONAL
Chicago, United States +4 more
Started: Aug 11, 2016
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
NCT04241185ACTIVE NOT RECRUITINGPHASE3
520 participants
INTERVENTIONAL
Washington D.C., United States +133 more
Started: May 19, 2020
Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer
NCT02560636ACTIVE NOT RECRUITINGPHASE1
34 participants
INTERVENTIONAL
Sutton, United Kingdom
Started: Jun 6, 2016
Pembrolizumab in Muscle-invasive Bladder Cancer
NCT05406713ACTIVE NOT RECRUITINGPHASE2
46 participants
INTERVENTIONAL
Duarte, United States +3 more
Started: Jul 13, 2022
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NCT05215574ACTIVE NOT RECRUITINGPHASE1
130 participants
INTERVENTIONAL
Gilbert, United States +8 more
Started: Mar 31, 2022
Completed Clinical Trials
7 completed trials for Pembrolizumab (Keytruda) in Bladder cancer
Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma
NCT02736266COMPLETEDPHASE2
174 participants
INTERVENTIONAL
Milan, Italy
Started: Feb 27, 2017
MK-3475/BCG in High Risk Superficial Bladder Cancer
NCT02324582COMPLETEDPHASE1
18 participants
INTERVENTIONAL
Springfield, United States +2 more
Started: Jun 1, 2015
Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)
NCT02625961COMPLETEDPHASE2
296 participants
INTERVENTIONAL
Started: Feb 10, 2016
Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab
NCT03212651COMPLETEDPHASE2
41 participants
INTERVENTIONAL
Villejuif, France
Started: Oct 17, 2017
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
NCT02178722COMPLETEDPHASE1, PHASE2
444 participants
INTERVENTIONAL
La Jolla, United States +23 more
Started: Jul 17, 2014
Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy
NCT03319745COMPLETEDPHASE2
23 participants
INTERVENTIONAL
Houston, United States
Started: Jan 11, 2018
Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma
NCT02619253COMPLETEDPHASE1
52 participants
INTERVENTIONAL
Los Angeles, United States +3 more
Started: Feb 23, 2016
Showing 20 of 126 total trials